OMN6 – the Next-Generation of Antibiotic Drugs

OMN6 is a novel antimicrobial peptide developed for IV administration in hospitalized patients suffering from severe or life-threatening infections involving Multi-Drug-Resistant bacteria

OMN6 is effective and safe. Targeting a huge, urgent unmet need, OMN6 eliminates resistan

  • Infection prevention
  • Antimicrobial compounds
  • Alternative antimicrobials

  • Bacteria
  • Fungi
  • Yeasts

  • Human
  • Veterinary
  • AgriFood
  • Environmental

Development stage:
  • Development

  • Company

  • License, Co-develop, Joint Venture, Sell

Big-pharma or a strategic-player that has the experience and expertise to join us in bringing a life-saving antibiotic drug to the market

Omnix Medical is a privately-owned biotechnology company developing the next-generation antibiotics against Multi Drug Resistant bacteria

Omnix is developing a pipeline of anti-infective compounds at different stages of the development route

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!